Plain-English translation of NCT03093688 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new immunotherapy approach using two types of immune cells—iNKT cells and CD8+ T cells—that are grown in the laboratory and then infused back into patients with advanced solid tumors. These immune cells are designed to recognize and attack cancer cells directly. Researchers want to see if this treatment is safe and whether it can help control advanced cancers that have not responded well to standard treatments like surgery, chemotherapy, or radiation.
Standard cancer treatments like surgery, chemotherapy, and radiation have limited effectiveness against advanced solid tumors. This medication represents a newer approach called immunotherapy, which harnesses your own immune system to fight cancer rather than relying solely on chemotherapy or radiation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive infusions of the specially grown immune cells as the study treatment. You will need to have your tumor tissue confirmed by a pathology lab and pass baseline blood tests and health evaluations to ensure you are safe to receive the infusions. After receiving the treatment, you will be followed closely for up to one year with visits to monitor your safety, how well you tolerate the treatment, and whether your cancer is responding.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
China